Search the Newsreel

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN)

AstraZeneca reported solid Q2 2026 core EPS growth, but faces significant risks due to the patent expiry of its key treatment, Farxiga, in the U.S. and its inclusion in China's procurement program. While the company's weight loss drug candidate offers some positive offsets, the …

AstraZeneca Q2 2026 earnings beat on cancer drug sales

AstraZeneca reported second-quarter results on Monday that topped profit expectations, with the Anglo-Swedish pharmaceutical company holding its 2026 guidance and $80 billion annual revenue target for 2030. Core earnings per share reached $2.63 for the three months ended June 30, a gain of 18% …

Earnings live: AstraZeneca stock rises to kick off a busy earnings week

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

Earnings live: LVMH sales grow as US luxury shoppers boost results

Earnings season kicks into high gear this week. AstraZeneca (AZN) and Nucor (NUE) report on Monday, with results from SK Hynix (SKHY), Visa (V), Coca-Cola (KO), Boeing (BA), Ford (F), ExxonMobil (XOM), and Chevron (CVX) coming later in the week. The main focus, though, …

AstraZeneca profit rises on strong cancer drug sales

AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs. Profit after tax climbed more than two percent …

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01 is the first Phase III trial to show overall survival benefit with an anti-CLDN18.2 ADC in this setting First pivotal readout from AstraZeneca's wholly owned …

AstraZeneca results: H1 and Q2 2026

Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030 CAMBRIDGE, England, July 27, 2026--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary H1 2026 % Change Q2 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 28,896 …

AstraZeneca sales rise as demand for cancer treatments grow

AstraZeneca has revealed that demand for its range of cancer treatments buoyed sales this year as the drugs giant increased spending on new research. The Cambridge-based company said sales growth within its oncology and rare disease divisions helped deliver a boost. It reported total …

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share grew from last year with higher revenues, excluding weak China results. Further, the firm confirmed fiscal 2026 outlook for …

AstraZeneca PLC declares $1.06 interim dividend

* AstraZeneca PLC (AZN [https://seekingalpha.com/symbol/AZN]) declares a $1.06/share interim dividend [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html]. * Payable Sept. 8; for shareholders of record Aug. 7; ex-div Aug. 7. * Looking ahead for FY 2026, the company intends to increase its total annual dividend payout to $3.30 per share. …

Earnings Snapshot: AstraZeneca reports Q2 earnings beat, raises interim dividend, and reaffirms FY26 guidance

[Seeking Alpha] Seeking Alpha (Seeking Alpha) MORE ON ASTRAZENECA PLC * AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback [https://seekingalpha.com/article/4922348-astrazeneca-oncology-engine-keeps-running-despite-wainua-setback] * AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldn't Panic [https://seekingalpha.com/article/4921003-astrazeneca-and-ionis-pharma-rocked-by-heart-disease-fail-why-you-shouldnt-panic] * AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy …

AstraZeneca Q2 Non-GAAP EPS tops expectations by $1.36; reconfirms full-year outlook

* AstraZeneca PLC press release [https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html] (AZN [https://seekingalpha.com/symbol/AZN]): Q2 Non-GAAP EPS of $2.63 beats by $1.36. * Revenue of $15.38B (+6.4% Y/Y) misses by $50M. * Interim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK). * FY2026 Revenue estimated growth …

AstraZeneca shares climbs as full-year outlook reiterated despite recent trial failure - UPDATE

AstraZeneca's shares rose after the drugmaker reported better-than-expected second-quarter earnings, driven by strong growth in oncology and rare diseases. Despite a recent trial failure that impacted its valuation, the company reiterated its full-year revenue and core earnings per share growth outlook. CEO Pascal Soriot …

AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation (NYSE:AZN) 2026-07-27

AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth (AZN:NYSE)

AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues. Looking ahead for fiscal 2026, AstraZeneca continues to expect total revenue to increase by a mid-to-high single-digit percentage, and core earnings per share …

Astrazeneca: Q2 Earnings Snapshot

This article provides a brief earnings snapshot for Astrazeneca's Q2 results. However, the actual financial details and performance metrics are not included in the provided text.

AstraZeneca's Q2 revenue rises 6% to $15.4B

AstraZeneca reported a 6% increase in its second-quarter revenue, reaching $15.4 billion. This financial update indicates continued growth for the pharmaceutical company.

Earnings Flash (AZN.L) AstraZeneca PLC Reports H1 Revenue $30.67B

AstraZeneca PLC (AZN.L) reported its H1 revenue to be $30.67 billion. This financial update comes alongside recent news regarding the company's drug trials, including Ultomiris missing its primary endpoint in a late-stage trial. Despite some setbacks, AstraZeneca posted a rise in H1 profit and …

AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?

(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026. AstraZeneca, as a biopharmaceutical company, offers multiple products for oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and therapies for rare diseases. AstraZeneca's blockbuster …

AZN|AstraZeneca PLC|Price:169.260|Chg%:+0.720

AstraZeneca PLC's stock (AZN) closed at $169.260, up 0.43% on July 24th, with a market capitalization of $525.04B. Despite recent market underperformance, the company boasts healthy fundamentals, high growth potential, and significant institutional ownership. Analysts maintain a "Buy" rating with a target price indicating …

Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AstraZeneca PLC (AZN) after the company announced its Phase-3 CARDIO-TTransform trial for Wainua failed to meet its primary endpoint. This news led to a 5.7% drop in AstraZeneca's American Depositary …

AstraZeneca (LSE:AZN) Wins EU Approval For Etcamah In Advanced Breast Cancer

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca received EU approval for Etcamah (camizestrant) in combination with CDK4/6 inhibitors for ER-positive, HER2-negative advanced breast cancer. The decision is based on Phase III SERENA-6 trial …

EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer

AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer. The EC approved Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for …

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca's Enhertu plus pertuzumab would become …

AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large …

AstraZeneca stock forecast: Consolidation near GBX12,547 support

Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide

By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. …

AstraZeneca PLC expected to post earnings of $2.54 a share - Earnings Preview

AstraZeneca PLC is projected to report earnings of $2.54 per share. This information comes from a Refinitiv earnings preview.

How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story

Ionis Pharmaceuticals and AstraZeneca recently reported that their Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin amyloidosis cardiomyopathy did not meet its primary efficacy endpoint, prompting a shareholder investigation into the transparency of trial data and design. This setback removes a late-stage cardiovascular candidate …

EU Okays AstraZeneca’s Etcamah As US Wait Continues

The European Union has approved AstraZeneca's drug Etcamah. This approval comes as the United States' decision on the drug is still pending. The article highlights this significant regulatory milestone for AstraZeneca.

Etcamah approval: AstraZeneca (NASDAQ: AZN) wins EU OK in HR+ breast cancer

AstraZeneca's Etcamah (camizestrant), combined with a CDK4/6 inhibitor, has received EU approval for the 1st-line treatment of adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer demonstrating an emergent ESR1 mutation and no disease progression on endocrine therapy. This approval is based …

AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer

(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union or EU for the treatment of adult patients for an advanced breast …

REG - AstraZeneca PLC - Etcamah approved in the EU for ER+ breast cancer

AstraZeneca's Etcamah (camizestrant), in combination with a CDK4/6 inhibitor, has received approval in the EU for treating adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation. This approval, based on the SERENA-6 Phase III trial, demonstrated a 56% …

Jefferies says September lung data can offset AstraZeneca trial failure

Jefferies believes that forthcoming detailed data on AstraZeneca's experimental lung drug, tozorakimab, could mitigate the impact of a recent heart trial failure. The bank reiterated its "buy" rating and a 17,500p price target, citing the drug's potential to treat chronic obstructive pulmonary disease regardless …

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.50 per share in its upcoming report, which indicates a year-over-year increase of 14.7%. Revenues are expected to be $15.31 billion, up 5.9% from the year-ago quarter. The current level reflects a downward …